Back to top
GSK PLC Sponsored ADR (GSK)
(Real Time Quote from BATS)
$38.57 USD
38.57
568,605
-0.39 (-1.00%)
Updated Oct 18, 2024 10:44 AM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.57 USD
-0.39 (-1.00%)
Updated Oct 18, 2024 10:44 AM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates
by Kinjel Shah
Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)
Amgen (AMGN)/AstraZeneca's Asthma Drug Gets FDA Priority Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Amgen (AMGN)/AstraZeneca's BLA for tezepelumab for the treatment of asthma.
Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More
by Zacks Equity Research
The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).
Merck's (MRK) Keytruda Gets FDA Nod for Advanced Skin Cancer
by Zacks Equity Research
Merck (MRK) gets approval from the FDA for the label expansion of Keytruda as a monotherapy for treating patients with locally advanced cutaneous squamous cell carcinoma.
Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases
by Zacks Equity Research
Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ¿¿¿ for treating various neurodegenerative diseases. Stock up.
Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications
by Zacks Equity Research
Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.
Merck (MRK) to Withdraw a Gastric Cancer Indication for Keytruda
by Zacks Equity Research
Merck's (MRK) Keytruda is approved under FDA's accelerated pathway for recurrent gastric or gastroesophageal junction adenocarcinoma indication but fails in post-marketing commitment study.
CureVac (CVAC) Announces Final Analysis of its COVID-19 Vaccine Study
by Zacks Equity Research
CureVac (CVAC) announces final analysis from its HERALD study on CVnCoV showing efficacy of 48%.
3 Big Drugmakers Likely to be in Focus in Second Half of 2021
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.
Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU (Revised)
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study
Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study
Pfizer (PFE) Begins Dosing in Prostate Cancer Drugs Study
by Zacks Equity Research
Pfizer (PFE) is developing its oral PARP inhibitor, talazoparib (Talzenna), in combination with Xtandi as a potential treatment for castration-sensitive prostate cancer in a late-stage study.
Company News for Jun 24, 2021
by Zacks Equity Research
Companies in The News Are: PDCO,GSK,SHAK,SON
Pharma Stock Roundup: EU Nod to AZN, SNY, JNJ Drugs, Glaxo's New COVID-19 Drug Data
by Kinjel Shah
EU approves AstraZeneca's (AZN) rare disease drug, Koselugo and expanded use of J&J's (JNJ) Darzalex Faspro and Sanofi's (SNY) Aubagio.
Sanofi (SNY)/Translate Bio Begin Study on mRNA Flu Vaccine
by Zacks Equity Research
Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.
Halozyme (HALO) Inks Collaboration Deal With Glaxo's HIV Unit
by Zacks Equity Research
Halozyme (HALO) and Glaxo's HIV company, ViiV Healthcare sign a collaboration agreement, which gives the latter exclusive right to Halozyme's ENHANZE technology to develop therapies targeting HIV
The Zacks Analyst Blog Highlights: Exxon Mobil, Texas Instruments, GlaxoSmithKline, Norfolk Southern and Corning
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, Texas Instruments, GlaxoSmithKline, Norfolk Southern and Corning
Top Stock Reports for Exxon Mobil, Texas Instruments & GlaxoSmithKline
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Texas Instruments (TXN), and GlaxoSmithKline (GSK).
Theravance (TBPH) COVID-19 Therapy Fails in Mid-Stage Study
by Zacks Equity Research
Theravance's (TBPH) JAK inhibitor candidate, nezulcitinib, fails to achieve statistically significant improvement in the number of respiratory failure-free days in hospitalized COVID-19 patients with lung injury.
Glaxo (GSK)/Vir Affirm COVID-19 Drug Cuts Hospitalization/Death
by Zacks Equity Research
Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make better HIV medicines.
Gilead (GILD) Veklury Data Positive in Hospitalized COVID Patients
by Zacks Equity Research
Gilead (GILD) announces positive data on Veklury in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets.
Pharma Stock Roundup: AZN COVID-19 Antibody Cocktail Failure, GSK New Cancer Deal
by Kinjel Shah
AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.
CureVac (CVAC) Plummets on Disappointing COVID-19 Vaccine Data
by Zacks Equity Research
CureVac (CVAC) down as it announces that its first-generation COVID-19 vaccine candidate, CVnCoV, did not meet the prespecified statistical success criteria in a phase IIb/III study.
Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.
Regeneron (REGN) Announces Data on COVID-19 Antibody Cocktail
by Zacks Equity Research
Regeneron (REGN) announces positive results from a phase III study on antibody cocktail, REGEN-COV.